KẾT QUẢ HÓA TRỊ DẪN ĐẦU PHÁC ĐỒ GEMCITABIN-CISPLATIN UNG THƯ VÒM MŨI HỌNG GIAI ĐOẠN III-IV(M0) TẠI BỆNH VIỆN UNG BƯỚU NGHỆ AN

Abstract

Objective: Treatment results and adverse effects of gemcitabine-cisplatin induction chemotherapy on patients with stage III-IV (M0) nasopharynx cancer at Nghe An Oncology Hospital. Subjects and methods: clinical trial, retrospective, study on 39 patients with stage III-IV (M0) nasopharynx cancer who received 3 cycle induction chemotherapy gemcitabine-cisplatin at the hospital. Nghe An Oncology Hospital from January 2020 to May 2022. Patients were assessed for response according to Recist 1.1 criteria, toxicity based on Common Terminology Criteria for Adverse Events v.5.0 (CTCAE) classification. Results: Overall response rate was 94.9%, Total response rate in tumor and node are 91.3% and 84.6%.  leukopenia (59%), anemia (30.8%) and thrombocytopenia (12.9%). Most toxicity grade 1,2. 1/39 patients with grade 1 elevation of creatinine, 25.6% of patients with grade 1 elevation of liver enzymes after chemotherapy, common side effects include nausea (94.8%), vomiting (64.1%), mainly grade 1. Conclusion: gemcitabine-cisplatin regimen induction chemotherapy in patients with stage III-IV (M0) nasopharynx cancer has a high response rate, well tolerated, mild toxicity, mainly on the hematopoietic system.